Animal & Plant Derived Vaccines
It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.
Related Conference of Animal & Plant Derived Vaccines
7th World Congress on Neuroimmunology and Neuroinfectious Diseases
Animal & Plant Derived Vaccines Conference Speakers
Recommended Sessions
- Animal & Plant Derived Vaccines
- Animal Models & Clinical Trials
- Antibodies: Engineering & Therapeutics
- Cancer, Malaria & TB Vaccines
- Cellular Immunology & Latest Innovations
- Combination & Conjugate Vaccines
- Current Research & Future Challenges
- DNA & Synthetic Vaccines
- Fish & Poultry Vaccines
- Geriatric Immunization
- HIV Vaccines
- Paediatric Vaccination
- Travel & Edible Vaccines
- Vaccine Production & Development
- Vaccine Safety & Efficacy
- Vaccines & Autism
- Vaccines against Drugs‎
- Vaccines against Infectious Diseases
- Vaccines for Immune Mediated Diseases
- Vaccines for Pregnant Women & Neonates
- Vaccines for Unconventional Diseases
- Vectors, Adjuvants & Delivery Systems
Related Journals
Are you interested in
- Advances in Neuroimaging and Diagnostic Techniques - Neuroimmunology Congress 2026 (France)
- Advances in Neuroimmunology and Neuroinflammation - Neuroimmunology Congress 2026 (France)
- Artificial Intelligence and Data-Driven Approaches in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Autoimmune Neurological Disorders and Therapeutic Advances - Neuroimmunology Congress 2026 (France)
- Biomarkers and Precision Medicine in Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Case Studies and Clinical Practice in Neuroimmunology and Neuroinfectious Diseases - Neuroimmunology Congress 2026 (France)
- Clinical Trials and Drug Development in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- CNS Infections: Diagnosis, Management, and Prevention - Neuroimmunology Congress 2026 (France)
- Emerging Technologies and Future Directions in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Ethical Considerations and Future Perspectives in Neuroimmunology Research - Neuroimmunology Congress 2026 (France)
- Immunogenetics and Neuroimmune Interactions - Neuroimmunology Congress 2026 (France)
- Immunotherapy and Novel Treatment Strategies - Neuroimmunology Congress 2026 (France)
- Microbiome and the Gut-Brain-Immune Axis - Neuroimmunology Congress 2026 (France)
- Neurodegeneration and Immune System Interactions - Neuroimmunology Congress 2026 (France)
- Neuroimmunology in Pediatric Disorders - Neuroimmunology Congress 2026 (France)
- Neuroinfectious Diseases and Global Health Challenges - Neuroimmunology Congress 2026 (France)
- Public Health, Policy, and Global Collaboration in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Rehabilitation and Long-Term Management of Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Translational Research and Clinical Applications in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Young Researchers, Innovation, and Emerging Ideas - Neuroimmunology Congress 2026 (France)
